- Home
- Companies
- Enable Injections
- Articles
Enable Injections articles
Sanofi-backed Enable Injections has gone big with its series C round. Three years after Sanofi led its series B, Enable Injections has raised a $215 million round to fund work on subcutaneous drug delivery system enFuse.
Enable Injections’ device consists of a wearable delivery disc and a system for transferring the drug from its original vessel. Users
Enable ultimately aims to increase healthcare provider efficiencies, minimise patient exposure in the clinic, and reduce healthcare costs, with the aim of benefiting patients and healthcare providers worldwide.
CEO and president Mike Hooven said the funding: “will help enFuse continue to redefine intravenous drug delivery by meaningfully scaling our development and commercialisation efforts”.
He continued: “This
Citation: Huddleston M, Estep J, “Drug Delivery: What do Patients and Providers Want?” ONdrugDelivery, Issue 124 (Sep 2021), pp 10–14.
Matthew Huddleston and Jennifer Estep discuss current drug delivery options and the value of convenient care.
Worldwide, patient and provider preferences are changing due to the covid-19 pandemic. Th